Status:
COMPLETED
Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia
Lead Sponsor:
Urovant Sciences GmbH
Conditions:
Overactive Bladder
Eligibility:
MALE
45+ years
Phase:
PHASE3
Brief Summary
This study will assess the long-term safety of vibegron when dosed up to 52 weeks in men with overactive bladder (OAB) symptoms on pharmacological therapy for Benign Prostatic Hyperplasia (BPH) who pr...
Eligibility Criteria
Inclusion
- Participant has completed participation of the 24-week double-blind treatment period in Study URO-901-3005 (NCT03902080) and demonstrated compliance with the study procedures and study medication schedule in the opinion of the investigator.
- Participant is capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
- Participant has the ability to continue to receive a stable dose of Benign Prostatic Hyperplasia (BPH) treatment with either a) alpha blocker monotherapy or b) alpha blocker +5-ARI.
- In the opinion of the investigator, the participant is able and willing to comply with the requirements of the protocol, including completing study questionnaires and the Bladder Diary.
Exclusion
- Participant experienced any Serious Adverse Event in Study URO-901-3005 that was reported as "possibly or probably related" to study treatment by the investigator.
- Participant is using any prohibited medications
- Participant has uncontrolled hyperglycemia (defined as fasting blood glucose \>150 milligrams per deciliter \[mg/dL\] or 8.33 millimoles per Liter \[mmol/L\] and/or non-fasting blood glucose \>200 mg/dL or 11.1 mmol/L) based on most recent available lab results in Study URO-901-3005 or uncontrolled in the opinion of the investigator.
- Participant has uncontrolled hypertension (systolic blood pressure of ≥180 millimeters of mercury \[mmHg\] and/or diastolic blood pressure of ≥100 mmHg) or has a resting heart rate (by pulse) \>100 beats per minute.
- Participant has systolic blood pressures ≥160 mmHg but \<180 mmHg, unless deemed by the investigator as safe to proceed in this study and able to complete the study per protocol.
- Participant has current evidence of any clinically significant condition, therapy, lab abnormality, or other circumstances that might, in the opinion of the investigator, confound the results of the study, interfere with the participant's ability to comply with study procedures, or make participation in the study not in the participant's best interest.
Key Trial Info
Start Date :
September 19 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 29 2022
Estimated Enrollment :
276 Patients enrolled
Trial Details
Trial ID
NCT04103450
Start Date
September 19 2019
End Date
July 29 2022
Last Update
August 21 2024
Active Locations (35)
Enter a location and click search to find clinical trials sorted by distance.
1
Private Practice
Huntsville, Alabama, United States, 35801
2
Clinical Trials Research
Lincoln, California, United States, 95648
3
American Institute of Research
Los Angeles, California, United States, 90017
4
Tri Valley Urology Medical Group
Murrieta, California, United States, 92562